Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/8/2014 |
| Start Date: | December 2011 |
| End Date: | July 2023 |
| Contact: | US GSK Clinical Trials Call Center |
| Email: | GSKClinicalSupportHD@gsk.com |
| Phone: | 877-379-3718 |
A Prospective, Exploratory Observational Study Evaluating Specific Biomarkers in Primary Invasive Breast Cancer and Their Modulation by Standard Neoadjuvant Therapy
This study will examine specific biomarkers in primary invasive breast cancer and explore
their correlation with patient outcome following standard neoadjuvant treatment.
their correlation with patient outcome following standard neoadjuvant treatment.
Inclusion Criteria:
- The patient has 18 years of age or older at the time of consent.
- The patient has provided pre-treatment tumor samples for WT1 expression screening and
gene expression profiling in the context of the NCT01220128 study.
- The patient has a histologically or cytologically confirmed primary invasive breast
cancer.
- The patient has provided written informed consent before any new information or new
material is provided to the Sponsor.
- The patient is planned to receive, is receiving or has received standard and/or
investigational therapy for breast cancer.
- The patient is planned to receive, is receiving or has received standard and/or
investigational therapy for breast cancer.
Exclusion Criteria:
Not applicable.
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials